Internal Medicine Department, Rochester General Hospital, Rochester, NY, USA.
Evidence-based medicine, Mayo Clinic School of Medicine, Rochester, MN, USA.
J Intensive Care Med. 2023 Nov;38(11):1068-1077. doi: 10.1177/08850666231182380. Epub 2023 Jun 23.
Patients with acute heart failure (AHF) exacerbation are susceptible to complications in the setting of COVID-19 infection. Data regarding the clinical outcomes of COVID-19 in patients admitted with AHF is limited. We used the national inpatient sample database by utilizing ICD-10 codes to identify all hospitalizations with a diagnosis of AHF in 2020. We classified the sample into AHF with COVID-19 infection versus those without COVID-19. Primary outcome was in-hospital mortality. Secondary outcomes were acute myocardial infarction, need for pressors, mechanical cardiac support, cardiogenic shock, and cardiac arrest. Also, we evaluated for acute pulmonary embolism (PE), bacterial pneumonia, need for a ventilator, and acute kidney injury (AKI). We identified a total of 694,920 of AHF hospitalizations, 660,463 (95.04%) patients without COVID-19 and 34,457 (4.96%) with COVID-19 infection. For baseline comorbidities, diabetes mellitus, chronic heart failure, ESRD, and coagulopathy were significantly higher among AHF patients with COVID-19 ( < .01). While CAD, prior MI, percutaneous coronary intervention, and coronary artery bypass graft, atrial fibrillation, chronic obstructive pulmonary disease, and peripheral vascular disease were higher among those without COVID-19. After adjustment for baseline comorbidities, in-hospital mortality (aOR 5.08 [4.81 to 5.36]), septic shock (aOR 2.54 [2.40 to 2.70]), PE (aOR 1.75 [1.57 to 1.94]), and AKI (aOR 1.33 [1.30 to 1.37]) were significantly higher among AHF with COVID-19 patients. The mean length of stay (5 vs 7 days, < .01) and costs of hospitalization ($42,143 vs $60,251, < .01) were higher among AHF patients with COVID-19 infection. COVID-19 infection in patients with AHF is associated with significantly higher in-hospital mortality, need for mechanical ventilation, septic shock, and AKI along with higher resource utilization. Predictors for mortality in AHF patients during the COVID-19 pandemic, COVID-19 infection, patients with end-stage heart failure, and atrial fibrillation. Studies on the impact of vaccination against COVID-19 in AHF patients are needed.
患有急性心力衰竭(AHF)恶化的患者在 COVID-19 感染的情况下容易出现并发症。关于 COVID-19 感染的 AHF 住院患者的临床结局的数据有限。我们利用国家住院患者样本数据库,使用 ICD-10 代码确定了 2020 年所有诊断为 AHF 的住院患者。我们将样本分为伴有 COVID-19 感染的 AHF 与不伴有 COVID-19 的 AHF。主要结局为住院期间死亡率。次要结局为急性心肌梗死、需要升压药、机械心脏支持、心源性休克和心脏骤停。此外,我们还评估了急性肺栓塞(PE)、细菌性肺炎、需要呼吸机和急性肾损伤(AKI)的情况。我们共确定了 694920 例 AHF 住院患者,其中 660463 例(95.04%)患者无 COVID-19 感染,34457 例(4.96%)有 COVID-19 感染。对于基线合并症,糖尿病、慢性心力衰竭、终末期肾脏疾病和凝血障碍在伴有 COVID-19 的 AHF 患者中明显更高( < .01)。而 CAD、前 MI、经皮冠状动脉介入治疗和冠状动脉旁路移植术、心房颤动、慢性阻塞性肺疾病和外周血管疾病在无 COVID-19 的患者中更高。在调整基线合并症后,住院期间死亡率(aOR 5.08 [4.81 至 5.36])、感染性休克(aOR 2.54 [2.40 至 2.70])、PE(aOR 1.75 [1.57 至 1.94])和 AKI(aOR 1.33 [1.30 至 1.37])在伴有 COVID-19 的 AHF 患者中明显更高。伴有 COVID-19 的 AHF 患者的平均住院时间(5 天与 7 天, < .01)和住院费用(42143 美元与 60251 美元, < .01)更高。COVID-19 感染与 AHF 患者的住院死亡率显著升高、需要机械通气、感染性休克和 AKI 以及更高的资源利用率有关。COVID-19 大流行期间 AHF 患者死亡的预测因素,COVID-19 感染,终末期心力衰竭患者和心房颤动。需要研究 COVID-19 疫苗接种对 AHF 患者的影响。